FDA Science Board Highlights Shortcomings At CDRH
This article was originally published in The Silver Sheet
Executive Summary
CDRH "STRATEGIC PLAN" IMPLEMENTATION will commence in earnest in February after senior center officials meet with an outside management consultant. The Center for Devices and Radiological Health has engaged the services of an organizational development expert to help translate the broad goals of the long-term strategic plan into workable milestones for the center’s various divisions and branches. At the same time, staffers are working to incorporate into the plan recommendations from an external review committee of the FDA Science Board on how to improve the science base of the center. The committee report advocates that CDRH institute major changes in its hiring and training of scientific personnel, use of outside expertise, oversight of combination products and internal assessment
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.